Close

NEWS

Istituto Biochimico Italiano G. Lorenzini changes ownership after 108 years, remaining an Italian excellence

22 July 2026

Press release 2026 July 22

ACS Dobfar S.p.A. acquires Istituto Biochimico Italiano G. Lorenzini (IBI) and its subsidiaries, marking a strategic step in its growth and strengthening its relationship with patients. Specializing in the development and production of pharmaceuticals, from the production of active ingredients to the preparation of pharmaceutical formulations, the ACS Dobfar Group operates 22 facilities worldwide, including 13 in Italy. The acquisition consolidates the Group's vertical integration strategy and strengthens its ability to ensure continuity and reliability of supplies, significantly increasing hospital turnover and expanding its presence in countries where IBI already operates directly, with the aim of offering patients a quality service.

The operation is part of a geopolitical context in which simply being the cheapest supplier is no longer enough: it is also necessary to be reliable and stable over time. Governments have increasingly recognized the strategic importance of pharmaceutical supply autonomy, and IBI's sales network, already present across several mainlands, will allow ACS Dobfar to produce significant volumes of injectable penicillin antibiotics. Italian products destined to reach patients all over the world will therefore be even more numerous.

This is a case that goes against the trend of manufacturing relocations abroad: two groups of Italian entrepreneurs are passing the baton to each other in managing products that require the highest quality, great responsibility, and constant investments to maintain regulatory standards. ACS Dobfar has faced similar challenges in the past and knows where to start to further strengthen its production chain. Both Groups have developed professionals with solid expertise, thanks to ongoing training, high standards, and a strong focus on the product: an asset of experience that will enable ACS Dobfar to become a major player in the antibiotics and sterile hospital products sector.

Latest news

undefined

Istituto Biochimico Italiano G. Lorenzini changes ownership after 108 years, remaining an Italian excellence

Read all
undefined

Seguiamo i farmaci fino a voi

Cinquanta milioni di investimento digitale e un forte impegno nella tracciabilità dei prodotti

Read all

See all news items

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!

CHIUDI

Private area

Sign up
Do not remember your password?
Cancel Log in

Log in to restricted area

Cancel Log in

Registration

Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the www.ibi-lorenzini.it website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address: www.ibi-lorenzini.it, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:

  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address: info@ibi-lorenzini.com.
  7. The Data Protection Officer may be contacted at the following e-mail address: dpo_ibi@protectiontrade.it

* Required fields

Cancel